Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV (Q40228687)
Jump to navigation
Jump to search
scientific article published on 25 April 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV |
scientific article published on 25 April 2017 |
Statements
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors (English)
Tatsuo Kanda
Shin Yasui
Masato Nakamura
Eiichiro Suzuki
Makoto Arai
Yoshihiko Ooka
Sadahisa Ogasawara
Tetsuhiro Chiba
Tomoko Saito
Yuki Haga
Koji Takahashi
Reina Sasaki
Shuang Wu
Shingo Nakamoto
Akinobu Tawada
Hitoshi Maruyama
Fumio Imazeki
Osamu Yokosuka
25 April 2017
1 reference
1 reference
1 reference